Hologic says a Massachusetts jury ruled against it in a patent infringement lawsuit, awarding damages of $4 million over the MyoSure device Hologic acquired along with Interlace Medical. A Massachusetts jury handed Hologic (NSDQ:HOLX) a $4 million setback today in a patent infringement battle with Smith & Nephew (FTSE:SN, NYSE:SNN) over Hologic’s MyoSure fibroid surgery device. The Bedford, Mass.-based women’s health giant bought the lawsuit along with Interlace Medical for $125 million in early 2011. Interlace developed the MyoSure device, a hysteroscopic system designed to remove fibroids — benign tumors of the uterus — in an out-patient procedure, using a high-speed cutting blade.
